Global Micro-Invasive Glaucoma Implants Market Segmentation, By Procedure (Trabecular Micro-Bypass Shunt, Hydrus Micro-Stent, Trabectome, Gonioscopy-Assisted Transluminal Traculomotomy, Kahook Dual Blade, Trab 360, Ab-Interno Canaloplasty, and Supraciliary Microstenting), Implant Model (Long, Thin Tube, and Large), End-User (Eye Hospitals, Opthalmology Clinics, and Outpatient Surgical Centers) – Industry Trends and Forecast to 2031.
Micro-Invasive Glaucoma Implants Market Analysis
The micro-invasive glaucoma implants market is experiencing substantial growth due to the rising prevalence of glaucoma and the increasing demand for minimally invasive surgical options. Micro-invasive glaucoma implants offer effective treatment solutions by providing controlled intraocular pressure reduction with minimal tissue disruption. Recent developments in this market include innovations such as the Hydrus Micro-Stent, which received FDA approval for its ability to improve outflow in the eye's drainage system, and advancements by companies such as Glaukos Corporation, which is pioneering new technologies in minimally invasive glaucoma surgery (MIGS). The market's expansion is further supported by increasing healthcare investments and a shift toward outpatient procedures. As more patients seek less invasive alternatives to traditional glaucoma surgeries, the adoption of micro-invasive implants is expected to rise, driven by their advantages in safety, efficacy, and reduced recovery times. These trends underscore the market’s dynamic growth and the ongoing innovation in glaucoma management technologies.
Micro-Invasive Glaucoma Implants Market Size
The global micro-invasive glaucoma implants market size was valued at USD 318.19 million in 2023 and is projected to reach USD 2611.66 million by 2031, with a CAGR of 30.10% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Micro-Invasive Glaucoma Implants Market Trends
“Rising Adoption of Minimally Invasive Surgical Techniques”
The global micro-invasive glaucoma implants market is experiencing significant growth, influenced by the increasing prevalence of glaucoma and the demand for less invasive treatment options. A notable trend in the market is the rising adoption of minimally invasive surgical techniques, which are gaining traction due to their lower risk of complications and quicker recovery times compared to traditional procedures. For instance, the Hydrus Micro-Stent, an innovative device introduced by iSTAR Medical, exemplifies this trend by providing effective intraocular pressure control with a micro-invasive approach. Such advancements are reshaping treatment paradigms, offering patients more efficient and comfortable solutions for managing their condition. As a result, the market is expanding rapidly, with key players focusing on developing cutting-edge implants that cater to the growing demand for safer and more effective glaucoma treatments.
Report Scope and Micro-Invasive Glaucoma Implants Market Segmentation
|
Attributes
|
Micro-Invasive Glaucoma Implants Key Market Insights
|
|
Segments Covered
|
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Key Market Players
|
Alcon (Switzerland), Bausch + Lomb (U.S.), Carl Zeiss Meditec AG (Germany), Johnson & Johnson Vision (U.S.), Lumenis Be Ltd. (Israel), Glaukos Corporation (U.S.), Lumibird Medical (France), IRIDEX Corporation (U.S.), Haag-Streit (Switzerland), Ziemer Ophthalmic Systems AG (Switzerland), Sonomed Escalon (U.S.), HumanOptics Holdings AG (Germany), BVI (U.S.), EssilorLuxottica (France), NIDEK CO., LTD. (Japan), Santen Pharmaceutical Co., Ltd. (Japan).
|
|
Market Opportunities
|
|
|
Value Added Data Infosets
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Micro-Invasive Glaucoma Implants Market Definition
Micro-invasive glaucoma implants are small, advanced medical devices designed to treat glaucoma through minimally invasive surgical techniques. These implants work by enhancing the outflow of aqueous humor from the eye, thereby reducing intraocular pressure (IOP) more effectively than traditional methods. They are inserted into the eye's drainage system using tiny incisions, offering a less invasive alternative to conventional glaucoma surgeries. The primary goal of these implants is to manage IOP with minimal disruption to surrounding tissues, promoting quicker recovery and reducing the risk of complications.
Micro-Invasive Glaucoma Implants Market Dynamics
Drivers
- Increasing Prevalence of Glaucoma
The increasing prevalence of glaucoma is a significant driver for the global micro-invasive glaucoma implants market. Glaucoma, a leading cause of blindness, affects over 70 million people worldwide, according to the World Health Organization. Such high incidence of glaucoma necessitates effective and advanced treatment options to manage intraocular pressure (IOP) and prevent vision loss. As traditional treatment methods may not always suffice, there is a growing demand for innovative solutions such as micro-invasive glaucoma implants. These implants provide a less invasive approach to controlling IOP, offering patients an effective alternative with fewer complications and faster recovery times. Consequently, the surge in glaucoma cases directly fuels the market for micro-invasive implants, as healthcare providers seek to meet the increasing demand for advanced, minimally invasive treatment options to improve patient outcomes and quality of life.
- Rising Geriatric Population
The rising geriatric population is a significant driver for the global micro-invasive glaucoma implants market. As the global population ages, the prevalence of age-related eye conditions, including glaucoma, is increasing. According to the World Health Organization (WHO), the number of people aged 60 years and older is expected to double by 2050, reaching approximately 2.1 billion. Such demographic shift results in a higher incidence of glaucoma, which is more common among older adults. For instance, the American Academy of Ophthalmology reports that People in their 70s have a 3 to 8 times higher prevalence of primary open-angle glaucoma (POAG), highlighting the growing need for effective treatment options. Micro-invasive glaucoma implants offer a minimally invasive approach to managing intraocular pressure (IOP) with fewer complications compared to traditional surgical methods. This makes them particularly appealing for elderly patients who may face higher risks with more invasive procedures. As the geriatric population expands, the demand for advanced, patient-friendly glaucoma treatments, such as micro-invasive implants, is anticipated to grow, driving market expansion.
Opportunities
- Expanding Global Healthcare Infrastructure Investments
The expansion of global healthcare infrastructure offers substantial opportunities for the micro-invasive glaucoma implants market. Increased investments in healthcare facilities are enhancing the availability of advanced medical technologies and improving access to specialized treatments. For instance, the World Bank's data indicates that global health expenditure has been growing steadily, with many countries allocating significant portions of their budgets to upgrade healthcare infrastructure. In regions such as Southeast Asia and Latin America, new hospitals and specialized eye care centers are being established, which support the integration of advanced glaucoma treatments. . As healthcare systems evolve, the increased availability and adoption of micro-invasive glaucoma implants become more feasible, thus driving market growth and enhancing patient access to innovative treatment options.
- Increasing Disposable Income Amog Individuals
The surge in disposable income among individuals presents a substantial opportunity for the global micro-invasive glaucoma implants market. As disposable income increases, particularly in emerging economies, consumers are more likely to invest in advanced healthcare solutions, including micro-invasive glaucoma implants. For instance, data from the World Bank indicates that global GDP per capita increased by 6.5% between 2020 and 2023, reflecting a rise in disposable income across many regions. Such financial uplift allows patients to afford innovative treatments that were previously out of reach. As individuals gain greater financial flexibility, they are increasingly willing to opt for minimally invasive procedures that offer quicker recovery and better outcomes, thus expanding the market for these advanced glaucoma treatments.
Restraints/Challenges
- Shortage of Skilled and Trained Professionals
Global micro-invasive glaucoma implants market is facing challenge regarding the shortage of skilled and trained professionals. The intricacies of micro-invasive glaucoma surgery (MIGS) require a high level of expertise in both advanced surgical techniques and the application of specialized implants. The Ophthalmology Journal reports a projected 30% shortfall in ophthalmologist full-time equivalents (FTEs) by 2035 compared to demand. Such shortage of qualified professionals and technicians affects the effective use and deployment of micro-invasive implants, impeding market growth.
- High Cost of Advanced Micro-Invasive Glaucoma Implants
The high cost of advanced micro-invasive glaucoma Implants poses a significant challenge in the global market, particularly for products incorporating antimicrobial properties or cutting-edge materials. These advanced dressings, designed to enhance wound healing and prevent infections, often come with a higher price tag due to the sophisticated technologies and materials involved. For instance, antimicrobial dressings that contain silver or honey can be substantially more expensive than traditional options. Such elevated cost can limit accessibility, especially in low-resource settings where healthcare budgets are constrained and insurance coverage may be insufficient. Consequently, patients in economically disadvantaged regions or those without adequate insurance may face difficulties obtaining these advanced dressings, potentially impacting their treatment outcomes and overall market growth.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Micro-Invasive Glaucoma Implants Market Scope
The market is segmented on the basis of procedures, implant model, and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Procedure
- Trabecular Micro-Bypass Shunt
- Hydrus Micro-Stent
- Trabectome
- Gonioscopy-Assisted Transluminal Traculomotomy
- Kahook Dual Blade
- Trab 360
- Ab-Interno Canaloplasty
- Supraciliary Microstenting
Implant Model
- Long
- Thin Tube
- Large
End-User
- Eye Hospitals
- Ophthalmology Clinics
- Outpatient Surgical Centers
Micro-Invasive Glaucoma Implants Market Regional Analysis
The market is analysed and market size insights and trends are provided by country, procedures, implant model, and end user as referenced above.
The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the market during the forecast period, driven by key factors such as the rapidly growing elderly population and a rising incidence of glaucoma. The region's market growth is further supported by the adoption of reimbursement models for ophthalmic care and stringent regulatory measures aimed at enhancing patient safety. These developments are expected to bolster the demand for ophthalmic devices in North America.
Asia-Pacific is anticipated to experience substantial growth from 2024 to 2031, driven by increased government investment in healthcare, a large and growing population, and a surge in reported cases of blindness and cataract surgeries. Additionally, advancements in medical technology and expanding access to eye care services are expected to further boost market growth. The region's commitment to improving healthcare infrastructure and rising awareness about eye health are also contributing to the optimistic outlook.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Micro-Invasive Glaucoma Implants Market Share
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
Micro-Invasive Glaucoma Implants Market Leaders Operating in the Market Are:
- Alcon (Switzerland)
- Bausch + Lomb (U.S.)
- Carl Zeiss Meditec AG (Germany)
- Johnson & Johnson Vision (U.S.)
- Lumenis Be Ltd. (Israel)
- Glaukos Corporation (U.S.)
- Lumibird Medical (France)
- IRIDEX Corporation (U.S.)
- Haag-Streit (Switzerland)
- Ziemer Ophthalmic Systems AG (Switzerland)
- Sonomed Escalon (U.S.)
- HumanOptics Holdings AG (Germany)
- BVI (U.S.)
- EssilorLuxottica (France)
- NIDEK CO., LTD. (Japan)
- Santen Pharmaceutical Co., Ltd. (Japan)
Latest Developments in Micro-Invasive Glaucoma Implants Market
- In July 2022, iSTAR Medical and AbbVie partenered to advance glaucoma treatment. This collaboration allowed AbbVie to substantially expand its portfolio of eye care products and offer glaucoma patients a broader range of treatment options.
- In January 2022, Alcon, Inc. acquired Ivantis, Inc. to enhance its portfolio of minimally invasive glaucoma surgery (MIGS) devices. By integrating Ivantis’ capabilities, Alcon seeks to expand its offerings in the glaucoma treatment market and improve patient outcomes with high-quality, minimally invasive surgical options.
SKU-